Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 10/20 | 0.50 |
| ▸ | SIK2 | Q9H0K1 | 11/20 | 0.48 |
| ▸ | SIK3 | Q9Y2K2 | 11/20 | 0.48 |
| ▸ | SIK1 | P57059 | 9/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928666 | 0.89 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL16809275 | 0.85 | SRC (0.56) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL24122681 | 0.82 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL17469517 | 0.81 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL21952671 | 0.81 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL11960310 | 0.80 | SRC (0.48) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL10064870 | 0.80 | SRC (0.52) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL11981518 | 0.79 | SORD (0.57) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL2237335 | 0.77 | SRC (0.47) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL1682840 | 0.77 | SRC (0.47) | SRCKITFLT3ABL1SIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SRC 51/4885KIT 1026/4885FLT3 125/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SRC 56/4885KIT 1143/4885FLT3 122/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SRC 56/4885KIT 1143/4885FLT3 122/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SRC 51/4885KIT 1026/4885FLT3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.